Warrant Exercise and Paydown of Debt

AI SummaryClose X

Allergy Therapeutics plc announced that lenders exercised 1,375,000,000 warrants, generating £55 million in proceeds for the company. These proceeds were used to fully repay the principal and accrued interest under the Shareholder Facility. Furthermore, a new £50 million uncommitted loan facility has been agreed with the lenders, providing financial flexibility through to 2030, with interest payable at 12 per cent. per annum and a repayment date of 15 October 2030. Following admission, the company's total issued and voting share capital will consist of 6,141,439,951 Ordinary Shares.

Disclaimer*

UK 100

Latest directors dealings